APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Transfusion Diagnosis for Donor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Transfusion Diagnosis for Donor Market Outlook and Growth Opportunities 2026

Report ID 174259800415 January 2026191 pages

Choose your research edition.

Industry ResearchTransfusion Diagnosis for Donor Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Transfusion Diagnosis for Donor Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Transfusion Diagnosis for Donor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Transfusion Diagnosis for Donor Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Transfusion Diagnosis for Donor Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Transfusion Diagnosis for Donor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Transfusion Diagnosis for Donor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Transfusion Diagnosis for Donor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Transfusion Diagnosis for Donor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Transfusion Diagnosis for Donor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Transfusion Diagnosis for Donor market include Grifols, F. Hoffmann-La Roche, Abbott, Bio-Rad Laboratories, Werfen, QuidelOrtho Corporation, AliveDx Holdings Finance, BAG Diagnostics GmbH and Diasorin, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Transfusion Diagnosis for Donor market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Transfusion Diagnosis for Donor and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Transfusion Diagnosis for Donor revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Transfusion Diagnosis for Donor market.

Transfusion Diagnosis for Donor Segment by Company

Grifols

F. Hoffmann-La Roche

Abbott

Bio-Rad Laboratories

Werfen

QuidelOrtho Corporation

AliveDx Holdings Finance

BAG Diagnostics GmbH

Diasorin

Prestige Diagnostics

Atlas Medical GmbH

Lorne Laboratories

Transfusion Diagnosis for Donor Segment by Type

Instruments

Kits and Reagents

Transfusion Diagnosis for Donor Segment by Application

Blood Banks

Blood Donation/Transfusion Centers

Others

Transfusion Diagnosis for Donor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Transfusion Diagnosis for Donor status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Transfusion Diagnosis for Donor key companies, revenue, market share, and recent developments.

3. To split the Transfusion Diagnosis for Donor breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Transfusion Diagnosis for Donor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Transfusion Diagnosis for Donor significant trends, drivers, influence factors in global and regions.

6. To analyze Transfusion Diagnosis for Donor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transfusion Diagnosis for Donor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Transfusion Diagnosis for Donor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transfusion Diagnosis for Donor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Transfusion Diagnosis for Donor industry.

Chapter 3: Detailed analysis of Transfusion Diagnosis for Donor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Transfusion Diagnosis for Donor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Transfusion Diagnosis for Donor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Transfusion Diagnosis for Donor Industry Trends Table 2. Transfusion Diagnosis for Donor Industry Drivers Table 3. Transfusion Diagnosis for Donor Industry Opportunities and Challenges Table 4. Transfusion Diagnosis for Donor Industry Restraints Table 5. Global Transfusion Diagnosis for Donor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Transfusion Diagnosis for Donor Revenue Share by Company (2021-2026) Table 7. Global Transfusion Diagnosis for Donor Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Transfusion Diagnosis for Donor Key Company Manufacturing Base & Headquarters Table 9. Global Transfusion Diagnosis for Donor Company, Product Type & Application Table 10. Global Transfusion Diagnosis for Donor Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Transfusion Diagnosis for Donor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Instruments Table 15. Significant Companies of Kits and Reagents Table 16. Global Transfusion Diagnosis for Donor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Transfusion Diagnosis for Donor Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Transfusion Diagnosis for Donor Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Transfusion Diagnosis for Donor Sales Value Share by Type (2021-2026) Table 20. Global Transfusion Diagnosis for Donor Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Blood Banks Table 22. Significant Companies of Blood Donation/Transfusion Centers Table 23. Significant Companies of Others Table 24. Global Transfusion Diagnosis for Donor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Transfusion Diagnosis for Donor Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Transfusion Diagnosis for Donor Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Transfusion Diagnosis for Donor Sales Value Share by Application (2021-2026) Table 28. Global Transfusion Diagnosis for Donor Sales Value Share by Application (2027-2032) Table 29. Global Transfusion Diagnosis for Donor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Transfusion Diagnosis for Donor Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Transfusion Diagnosis for Donor Sales Value Share by Region (2021-2026) Table 32. Global Transfusion Diagnosis for Donor Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Transfusion Diagnosis for Donor Sales Value Share by Region (2027-2032) Table 34. Global Transfusion Diagnosis for Donor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Transfusion Diagnosis for Donor Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Transfusion Diagnosis for Donor Sales Value Market Share by Country (2021-2026) Table 37. Global Transfusion Diagnosis for Donor Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Transfusion Diagnosis for Donor Sales Value Market Share by Country (2027-2032) Table 39. Grifols Company Information Table 40. Grifols Business Overview Table 41. Grifols Transfusion Diagnosis for Donor Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Grifols Transfusion Diagnosis for Donor Product Portfolio Table 43. Grifols Recent Development Table 44. F. Hoffmann-La Roche Company Information Table 45. F. Hoffmann-La Roche Business Overview Table 46. F. Hoffmann-La Roche Transfusion Diagnosis for Donor Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. F. Hoffmann-La Roche Transfusion Diagnosis for Donor Product Portfolio Table 48. F. Hoffmann-La Roche Recent Development Table 49. Abbott Company Information Table 50. Abbott Business Overview Table 51. Abbott Transfusion Diagnosis for Donor Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Abbott Transfusion Diagnosis for Donor Product Portfolio Table 53. Abbott Recent Development Table 54. Bio-Rad Laboratories Company Information Table 55. Bio-Rad Laboratories Business Overview Table 56. Bio-Rad Laboratories Transfusion Diagnosis for Donor Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Bio-Rad Laboratories Transfusion Diagnosis for Donor Product Portfolio Table 58. Bio-Rad Laboratories Recent Development Table 59. Werfen Company Information Table 60. Werfen Business Overview Table 61. Werfen Transfusion Diagnosis for Donor Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Werfen Transfusion Diagnosis for Donor Product Portfolio Table 63. Werfen Recent Development Table 64. QuidelOrtho Corporation Company Information Table 65. QuidelOrtho Corporation Business Overview Table 66. QuidelOrtho Corporation Transfusion Diagnosis for Donor Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. QuidelOrtho Corporation Transfusion Diagnosis for Donor Product Portfolio Table 68. QuidelOrtho Corporation Recent Development Table 69. AliveDx Holdings Finance Company Information Table 70. AliveDx Holdings Finance Business Overview Table 71. AliveDx Holdings Finance Transfusion Diagnosis for Donor Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. AliveDx Holdings Finance Transfusion Diagnosis for Donor Product Portfolio Table 73. AliveDx Holdings Finance Recent Development Table 74. BAG Diagnostics GmbH Company Information Table 75. BAG Diagnostics GmbH Business Overview Table 76. BAG Diagnostics GmbH Transfusion Diagnosis for Donor Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. BAG Diagnostics GmbH Transfusion Diagnosis for Donor Product Portfolio Table 78. BAG Diagnostics GmbH Recent Development Table 79. Diasorin Company Information Table 80. Diasorin Business Overview Table 81. Diasorin Transfusion Diagnosis for Donor Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Diasorin Transfusion Diagnosis for Donor Product Portfolio Table 83. Diasorin Recent Development Table 84. Prestige Diagnostics Company Information Table 85. Prestige Diagnostics Business Overview Table 86. Prestige Diagnostics Transfusion Diagnosis for Donor Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Prestige Diagnostics Transfusion Diagnosis for Donor Product Portfolio Table 88. Prestige Diagnostics Recent Development Table 89. Atlas Medical GmbH Company Information Table 90. Atlas Medical GmbH Business Overview Table 91. Atlas Medical GmbH Transfusion Diagnosis for Donor Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Atlas Medical GmbH Transfusion Diagnosis for Donor Product Portfolio Table 93. Atlas Medical GmbH Recent Development Table 94. Lorne Laboratories Company Information Table 95. Lorne Laboratories Business Overview Table 96. Lorne Laboratories Transfusion Diagnosis for Donor Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Lorne Laboratories Transfusion Diagnosis for Donor Product Portfolio Table 98. Lorne Laboratories Recent Development Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Transfusion Diagnosis for Donor Product Image Figure 2. Global Transfusion Diagnosis for Donor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Transfusion Diagnosis for Donor Market Size (2021-2032) & (US$ Million) Figure 4. Global Transfusion Diagnosis for Donor Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Instruments Image Figure 8. Kits and Reagents Image Figure 9. Global Transfusion Diagnosis for Donor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Transfusion Diagnosis for Donor Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Transfusion Diagnosis for Donor Sales Value Share by Type (2021-2032) Figure 12. Blood Banks Image Figure 13. Blood Donation/Transfusion Centers Image Figure 14. Others Image Figure 15. Global Transfusion Diagnosis for Donor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Transfusion Diagnosis for Donor Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Transfusion Diagnosis for Donor Sales Value Share by Application (2021-2032) Figure 18. Global Transfusion Diagnosis for Donor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Transfusion Diagnosis for Donor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Transfusion Diagnosis for Donor Sales Value (2021-2032) & (US$ Million) Figure 21. North America Transfusion Diagnosis for Donor Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Transfusion Diagnosis for Donor Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Transfusion Diagnosis for Donor Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Transfusion Diagnosis for Donor Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Transfusion Diagnosis for Donor Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Transfusion Diagnosis for Donor Sales Value (2021-2032) & (US$ Million) Figure 27. South America Transfusion Diagnosis for Donor Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Transfusion Diagnosis for Donor Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Transfusion Diagnosis for Donor Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Instruments
  • Kits and Reagents
Applications
  • Blood Banks
  • Blood Donation/Transfusion Centers
  • Others
Companies covered
  • Grifols
  • F. Hoffmann-La Roche
  • Abbott
  • Bio-Rad Laboratories
  • Werfen
  • QuidelOrtho Corporation
  • AliveDx Holdings Finance
  • BAG Diagnostics GmbH
  • Diasorin
  • Prestige Diagnostics
  • Atlas Medical GmbH
  • Lorne Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Transfusion Diagnosis for Donor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Transfusion Diagnosis for Donor Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Transfusion Diagnosis for Donor Market Dynamics
  1. 2.1 Transfusion Diagnosis for Donor Industry Trends
  2. 2.2 Transfusion Diagnosis for Donor Industry Drivers
  3. 2.3 Transfusion Diagnosis for Donor Industry Opportunities and Challenges
  4. 2.4 Transfusion Diagnosis for Donor Industry Restraints
3 Transfusion Diagnosis for Donor Market by Company
  1. 3.1 Global Transfusion Diagnosis for Donor Company Revenue Ranking in 2025
  2. 3.2 Global Transfusion Diagnosis for Donor Revenue by Company (2021-2026)
  3. 3.3 Global Transfusion Diagnosis for Donor Company Ranking (2024-2026)
  4. 3.4 Global Transfusion Diagnosis for Donor Company Manufacturing Base and Headquarters
  5. 3.5 Global Transfusion Diagnosis for Donor Company Product Type and Application
  6. 3.6 Global Transfusion Diagnosis for Donor Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Transfusion Diagnosis for Donor Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Transfusion Diagnosis for Donor Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Transfusion Diagnosis for Donor Market by Type
  1. 4.1 Transfusion Diagnosis for Donor Type Introduction
  2. 4.1.1 Instruments
  3. 4.1.2 Kits and Reagents
  4. 4.2 Global Transfusion Diagnosis for Donor Sales Value by Type
  5. 4.2.1 Global Transfusion Diagnosis for Donor Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Transfusion Diagnosis for Donor Sales Value by Type (2021-2032)
  7. 4.2.3 Global Transfusion Diagnosis for Donor Sales Value Share by Type (2021-2032)
5 Transfusion Diagnosis for Donor Market by Application
  1. 5.1 Transfusion Diagnosis for Donor Application Introduction
  2. 5.1.1 Blood Banks
  3. 5.1.2 Blood Donation/Transfusion Centers
  4. 5.1.3 Others
  5. 5.2 Global Transfusion Diagnosis for Donor Sales Value by Application
  6. 5.2.1 Global Transfusion Diagnosis for Donor Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Transfusion Diagnosis for Donor Sales Value by Application (2021-2032)
  8. 5.2.3 Global Transfusion Diagnosis for Donor Sales Value Share by Application (2021-2032)
6 Transfusion Diagnosis for Donor Regional Value Analysis
  1. 6.1 Global Transfusion Diagnosis for Donor Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Transfusion Diagnosis for Donor Sales Value by Region (2021-2032)
  3. 6.2.1 Global Transfusion Diagnosis for Donor Sales Value by Region: 2021-2026
  4. 6.2.2 Global Transfusion Diagnosis for Donor Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Transfusion Diagnosis for Donor Sales Value (2021-2032)
  7. 6.3.2 North America Transfusion Diagnosis for Donor Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Transfusion Diagnosis for Donor Sales Value (2021-2032)
  10. 6.4.2 Europe Transfusion Diagnosis for Donor Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Transfusion Diagnosis for Donor Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Transfusion Diagnosis for Donor Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Transfusion Diagnosis for Donor Sales Value (2021-2032)
  16. 6.6.2 South America Transfusion Diagnosis for Donor Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Transfusion Diagnosis for Donor Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Transfusion Diagnosis for Donor Sales Value Share by Country, 2025 VS 2032
7 Transfusion Diagnosis for Donor Country-level Value Analysis
  1. 7.1 Global Transfusion Diagnosis for Donor Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Transfusion Diagnosis for Donor Sales Value by Country (2021-2032)
  3. 7.2.1 Global Transfusion Diagnosis for Donor Sales Value by Country (2021-2026)
  4. 7.2.2 Global Transfusion Diagnosis for Donor Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Transfusion Diagnosis for Donor Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Transfusion Diagnosis for Donor Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Transfusion Diagnosis for Donor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Grifols
  2. 8.1.1 Grifols Company Information
  3. 8.1.2 Grifols Business Overview
  4. 8.1.3 Grifols Transfusion Diagnosis for Donor Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Grifols Transfusion Diagnosis for Donor Product Portfolio
  6. 8.1.5 Grifols Recent Developments
  7. 8.2 F. Hoffmann-La Roche
  8. 8.2.1 F. Hoffmann-La Roche Company Information
  9. 8.2.2 F. Hoffmann-La Roche Business Overview
  10. 8.2.3 F. Hoffmann-La Roche Transfusion Diagnosis for Donor Revenue and Gross Margin (2021-2026)
  11. 8.2.4 F. Hoffmann-La Roche Transfusion Diagnosis for Donor Product Portfolio
  12. 8.2.5 F. Hoffmann-La Roche Recent Developments
  13. 8.3 Abbott
  14. 8.3.1 Abbott Company Information
  15. 8.3.2 Abbott Business Overview
  16. 8.3.3 Abbott Transfusion Diagnosis for Donor Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Abbott Transfusion Diagnosis for Donor Product Portfolio
  18. 8.3.5 Abbott Recent Developments
  19. 8.4 Bio-Rad Laboratories
  20. 8.4.1 Bio-Rad Laboratories Company Information
  21. 8.4.2 Bio-Rad Laboratories Business Overview
  22. 8.4.3 Bio-Rad Laboratories Transfusion Diagnosis for Donor Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bio-Rad Laboratories Transfusion Diagnosis for Donor Product Portfolio
  24. 8.4.5 Bio-Rad Laboratories Recent Developments
  25. 8.5 Werfen
  26. 8.5.1 Werfen Company Information
  27. 8.5.2 Werfen Business Overview
  28. 8.5.3 Werfen Transfusion Diagnosis for Donor Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Werfen Transfusion Diagnosis for Donor Product Portfolio
  30. 8.5.5 Werfen Recent Developments
  31. 8.6 QuidelOrtho Corporation
  32. 8.6.1 QuidelOrtho Corporation Company Information
  33. 8.6.2 QuidelOrtho Corporation Business Overview
  34. 8.6.3 QuidelOrtho Corporation Transfusion Diagnosis for Donor Revenue and Gross Margin (2021-2026)
  35. 8.6.4 QuidelOrtho Corporation Transfusion Diagnosis for Donor Product Portfolio
  36. 8.6.5 QuidelOrtho Corporation Recent Developments
  37. 8.7 AliveDx Holdings Finance
  38. 8.7.1 AliveDx Holdings Finance Company Information
  39. 8.7.2 AliveDx Holdings Finance Business Overview
  40. 8.7.3 AliveDx Holdings Finance Transfusion Diagnosis for Donor Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AliveDx Holdings Finance Transfusion Diagnosis for Donor Product Portfolio
  42. 8.7.5 AliveDx Holdings Finance Recent Developments
  43. 8.8 BAG Diagnostics GmbH
  44. 8.8.1 BAG Diagnostics GmbH Company Information
  45. 8.8.2 BAG Diagnostics GmbH Business Overview
  46. 8.8.3 BAG Diagnostics GmbH Transfusion Diagnosis for Donor Revenue and Gross Margin (2021-2026)
  47. 8.8.4 BAG Diagnostics GmbH Transfusion Diagnosis for Donor Product Portfolio
  48. 8.8.5 BAG Diagnostics GmbH Recent Developments
  49. 8.9 Diasorin
  50. 8.9.1 Diasorin Company Information
  51. 8.9.2 Diasorin Business Overview
  52. 8.9.3 Diasorin Transfusion Diagnosis for Donor Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Diasorin Transfusion Diagnosis for Donor Product Portfolio
  54. 8.9.5 Diasorin Recent Developments
  55. 8.10 Prestige Diagnostics
  56. 8.10.1 Prestige Diagnostics Company Information
  57. 8.10.2 Prestige Diagnostics Business Overview
  58. 8.10.3 Prestige Diagnostics Transfusion Diagnosis for Donor Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Prestige Diagnostics Transfusion Diagnosis for Donor Product Portfolio
  60. 8.10.5 Prestige Diagnostics Recent Developments
  61. 8.11 Atlas Medical GmbH
  62. 8.11.1 Atlas Medical GmbH Company Information
  63. 8.11.2 Atlas Medical GmbH Business Overview
  64. 8.11.3 Atlas Medical GmbH Transfusion Diagnosis for Donor Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Atlas Medical GmbH Transfusion Diagnosis for Donor Product Portfolio
  66. 8.11.5 Atlas Medical GmbH Recent Developments
  67. 8.12 Lorne Laboratories
  68. 8.12.1 Lorne Laboratories Company Information
  69. 8.12.2 Lorne Laboratories Business Overview
  70. 8.12.3 Lorne Laboratories Transfusion Diagnosis for Donor Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Lorne Laboratories Transfusion Diagnosis for Donor Product Portfolio
  72. 8.12.5 Lorne Laboratories Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst